Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 5993 pMDI with/without Spacer in COPD
NCT02119234Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of beclomethasone dipropionate, formoterol and glycopyrronium bromide in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Area under the curve of B17MP, formoterol and glycopyrrolate at 48 hours. Started Mar 2014; status: completed.
02
Drugs
beclomethasone dipropionateformoterolglycopyrronium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02119234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02119234.